FloBiotech was founded by neuroscientists and biotech leaders united by a shared conviction: that grounding neurodegeneration research in human biology is essential to improving translation from discovery to development. The company brings together deep expertise across neuroscience, clinical translation, drug discovery, diagnostics, and company building to address the limitations that have held back progress in Alzheimer’s disease and related neurodegenerative diseases.
FloBiotech’s leadership team combines decades of experience spanning fundamental neuroscience, translational research, CNS drug development, diagnostics, company building, and life-sciences investment. Together, the team has led programs from early discovery through clinical development, built and scaled biotechnology companies, and established global research and industry partnerships. This breadth of experience underpins FloBiotech’s disciplined approach to advancing human-relevant science toward development-ready programs.
Loïc brings deep experience in building and scaling life-sciences companies across operations, strategy, and partnerships. He has held senior leadership roles at Myovant Sciences, Biofourmis, Flisom AG, and Smith & Nephew, including responsibility for global operations and strategic alliances. At FloBiotech, he leads corporate strategy, company building and capital formation, translating neuroscience innovation into an execution-ready organization.
Florence is a leading neuroscientist in tau biology and neurodegenerative disease, with over 20 years of experience spanning fundamental, translational, and therapeutic research. Her work has produced foundational contributions to the understanding of tau pathology, with publications in high-impact journals and international recognition, including the Best Young European Researcher award from Fondation Recherche Alzheimer. At FloBiotech, she defines the scientific strategy across the FloCells™ platform, ensuring biological rigor and translational relevance.
Andreas is a Swiss attorney-at-law with deep expertise in corporate law, IP strategy, governance, and regulatory frameworks for pharmaceutical and biotech companies. He has held senior legal and compliance roles within a Swiss listed pharmaceutical company and now advises biotech clients through his law firm. At FloBiotech, he is responsible for legal strategy, IP protection, compliance and corporate governance.
Baltazar is a physician-scientist and clinical neurologist with more than 30 years of experience in CNS drug development across academia and industry. He has led global translational and clinical programs at Novartis, contributing to the development of multiple approved therapies and advanced programs in Alzheimer’s, Parkinson’s, ALS, PSP, and rare neurological diseases. At FloBiotech, he guides translational strategy, drug discovery, and preclinical-to-clinical alignment for the Clusterin program.
Sally brings senior financial leadership experience across several international, high-growth, and innovation-driven organizations. She oversees financial strategy, governance, and operational discipline at FloBiotech, supporting capital efficiency, transparency, and long-term financial readiness.
Peter brings extensive experience in investor engagement, communications, and strategic storytelling across global organizations. He has worked closely with executive teams, boards, strategic partners, and investors to articulate complex strategies and growth narratives. At FloBiotech, he leads investor relations and partnerships, ensuring clear, consistent understanding of company objectives, scientific progress, milestones, and long-term value creation.
Elfareato is a seasoned healthcare executive with more than two decades of leadership experience across diagnostics, medical devices, and digital health. Formerly EVP & GM at GE HealthCare, he has built and scaled multi-billion-dollar businesses and led complex commercial transformations – now serving as Global GM and Head of Plasma Innovations at Terumo Blood and Cell Technologies. At FloBiotech, he drives the diagnostics strategy, connecting scientific discovery with translational and commercial pathways.
Stephanie is a senior business and operations leader with experience driving strategy, execution, and cross-functional alignment within global healthcare companies. At FloBiotech, she partners closely with the executive team to translate scientific and corporate priorities into coordinated execution as the company progresses.
Alan is a seasoned biopharmaceutical executive with a distinguished track record in company building, product commercialization, and value creation. He previously served as CEO of Emisphere Technologies, which was acquired by Novo Nordisk, and held senior leadership roles at Roche/Genentech. As Chairman, he provides strategic oversight and deep industry perspective to support FloBiotech’s long-term growth.
Matthew is a life-sciences investor and operator with a strong track record supporting early-stage biotech companies through hands-on execution and governance. At FloBiotech, he contributes board oversight alongside active involvement in operational planning and capital strategy.
Nick is a corporate lawyer and governance specialist with experience advising international organizations on corporate structure, regulatory compliance, and board governance. Based in the United Kingdom, where FloBiotech maintains a corporate entity, he brings legal and governance oversight that strengthens the company’s international corporate framework and long-term strategic development.
Carlos is a physician-executive with experience across clinical medicine, neuroscience, and life sciences commercialization. He brings clinical, translational, and commercial perspective to the board as FloBiotech advances toward development.
Haung Yu is a neuroscientist with extensive experience in neurodegeneration research. He contributes scientific insight and oversight to the board, supporting FloBiotech’s focus on human-relevant disease biology.
Brenda is an investment professional with experience across venture capital, growth equity, and board governance. She brings a strong investor perspective to the board, supporting capital strategy and long-term value creation at FloBiotech.